Executive Summary: Key Legal and Evidentiary Issues

• Disputed whether Yasmin and YAZ created a significantly increased risk of venous thromboembolism (VTE), arterial thromboembolism (ATE), and gallbladder disease compared to other oral contraceptives, sufficient to warrant different warnings.
• Extensive epidemiological evidence (including the EURAS and Ingenix studies) suggested no statistically significant increased risk, posing major hurdles for proving general causation at a common issues trial.
• Even if general causation were established, individual class members would still face substantial evidentiary challenges in proving specific causation and that additional warnings would have changed their behaviour.
• The court assessed whether a $9.05 million national settlement fund, with a streamlined points-based, non-adversarial claims process, was fair, reasonable, and in the best interests of the class.
• Judicial scrutiny extended to the proportionality and reasonableness of class counsel’s contingency fees and disbursements in light of the litigation’s complexity, risk, duration, and outcome.
• The court weighed a small number of objections against broad support from class members and the representative plaintiffs, considering concerns about adequacy of compensation versus the real litigation risks and delays avoided by settlement.

Facts of the case

Yasmin and YAZ are combined oral contraceptives sold in Canada. The plaintiffs commenced product liability class actions in Saskatchewan, Ontario and Quebec, alleging that these contraceptives were associated with increased risks of serious side effects, specifically blood clots (venous and arterial thromboembolism) and gallbladder disease. The defendants were Bayer entities involved in the marketing, distribution and sale of Yasmin and YAZ in Canada. The plaintiffs alleged the defendants were negligent in how the products were marketed, distributed and sold, and claimed damages for individuals who developed blood clots and gallbladder disease, along with derivative claims by family members under applicable family law statutes. The defendants denied these allegations throughout.

The Saskatchewan proceeding was commenced on 11 December 2009. After several applications, it was certified as a multi-jurisdictional class action on 15 October 2018, with two common issues identified for the class and Dawn Dembrowski appointed as representative plaintiff. The litigation ran in parallel with companion class actions in Ontario and Quebec, and all three actions advanced on the basis that Yasmin and YAZ allegedly posed greater risks than other available combined oral contraceptives and that the defendants had not adequately warned of those risks.

Procedural history and road to settlement

Over the course of more than 15 years, the action was hard-fought and progressed through contested certification proceedings and extensive discovery. The defendants vigorously opposed certification on all five statutory criteria under The Class Actions Act in Saskatchewan, reflecting the adversarial nature and complexity of the matter. Class counsel conducted extensive documentary discovery, reviewing over 40,000 documents and some 400,000 pages, which allowed them to assess the strength and weaknesses of the plaintiffs’ case and the defences the Bayer entities would raise at trial.

Settlement discussions between the parties were protracted and occurred at arm’s length. The parties exchanged multiple offers over a number of years before reaching a Settlement Agreement dated 30 July 2025. That agreement applied across the Saskatchewan, Ontario and Quebec class actions. It was subsequently approved in Ontario (Schwoob v Bayer Inc., 2025 ONSC 6607) and in Quebec (Guindon v Bayer Inc.), before coming before the Saskatchewan court for approval.

Structure of the settlement and claims process

The Settlement Agreement created a national Settlement Fund of $9,050,000 CAD. The fund was structured as follows: $8,139,000 was earmarked for the payment of compensation to approved settlement class member claims, as well as for administration expenses and class counsel fees as approved by the courts. A further $905,000 was allocated to provincial and territorial health insurers, to be divided among jurisdictions based on actual distribution of Yasmin and YAZ by province. In addition, a total of $6,000 was set aside as honoraria for the Ontario and Saskatchewan representative plaintiffs, to be divided equally between them.

The agreement was accompanied by a Benefits and Distribution Protocol designed to make the claims process accessible and relatively simple. Claims would be confidential, with claimants presumed to be acting in good faith, and a professional claims administrator evaluating all claims rather than an adversarial tribunal. Class members or their estates, as well as eligible family members, would be able to submit claims. To qualify for benefits, claimants had to provide evidence that they ingested Yasmin or YAZ during the applicable period and were subsequently diagnosed with one of the qualifying medical conditions.

A key feature of the protocol was that claimants would not be required to prove general causation (that Yasmin/YAZ increased risk compared to other contraceptives) or specific causation (that the products caused their particular injuries rather than other factors). Instead, compensation would be distributed using a points-based grid, with varying levels of compensation depending on the type and severity of qualifying medical conditions, and whether a qualifying fatality was involved. Compensation levels ranged from $500 for gallbladder disease to $13,500 for fatalities associated with venous thromboembolism. The protocol also provided for a reconsideration process by the claims administrator and set out how payments to provincial health insurers would be made. If funds remained after all approved claims and required payments, the balance would be distributed cy-près to the Women’s Health Collective Canada or another agreed-upon organization, subject to statutory obligations in Quebec.

The court was advised that class counsel were aware of approximately 2,000 potential settlement class members who might be eligible to submit claims. Epiq Class Action Services Canada Inc., an experienced class action administrator already familiar with the litigation through prior notice and objection processes, was proposed and ultimately appointed as the claims administrator.

Key legal and evidentiary considerations on settlement approval

Under The Class Actions Act, a class action settlement is not binding without court approval, and the court must be satisfied that it is fair, reasonable and in the best interests of class members. In assessing the proposed settlement, the court applied established factors, including the likelihood of recovery or success at trial, the amount and nature of the evidence and investigation to date, the terms and conditions of the settlement, the recommendations and experience of counsel, the future expense and duration of litigation, any neutral recommendations, the number and nature of objections, and the presence of arm’s-length bargaining without collusion.

A central substantive issue in the litigation was whether Yasmin and YAZ carried an increased risk of VTE, ATE or gallbladder disease when compared to other oral contraceptives, and whether any such increased risk was significant enough to require different warnings or would have altered class members’ decisions to use the products. The evidentiary record included several major epidemiological studies—such as EURAS, Ingenix, LASS and Jick et al.—which, on the summary before the court, did not show statistically significant increased risks for users of Yasmin and YAZ compared to users of other oral contraceptives. In particular, the EURAS study (mandated by European regulators) and the Ingenix study (required by U.S. regulators) were large, prospective studies tracking cohorts of users of Yasmin/YAZ and comparator contraceptives, and were regarded as especially reliable because they enabled control for confounding factors such as body mass index, family history and smoking status.

It was also relevant that Health Canada had never required updated labelling regarding alleged risks of arterial thromboembolism or gallbladder disease for Yasmin and YAZ, and that in a 2023 medical negligence case (McLean v Valadka), an Ontario court had found that alleged increased risks of blood clots associated with YAZ were not significant. Against this evidentiary backdrop, the Saskatchewan court agreed with the Ontario judge that the plaintiffs faced significant risks in attempting to prove general causation at a common issues trial.

Even if general causation could be established, individual class members would still have to prove specific causation—that the use of Yasmin or YAZ caused their personal injuries—and that an additional warning about incremental risk would have altered their choices. The court recognized that this would require complex, individualized assessments and would be vulnerable to the usual risks of lengthy litigation: fading memories, issues with witness availability, the unpredictability of trial testimony and potential appeals, all of which could delay any eventual compensation for years.

Objections, class member perspectives and policy clauses

Seven objections were received by mid-January 2026. These were mainly concerned that the settlement did not provide compensation proportionate to the severity of harms suffered. The court observed that these objections largely assumed that both general and specific causation could be proven and implied that the fact of injury alone necessarily warranted substantial compensation. In contrast, the representative plaintiffs supported the settlement after considering experienced counsel’s advice and their own long involvement in the litigation. Class counsel also reported that many class members did not object and instead expressed support for the settlement, as well as an intention to claim if it were approved. The court received a poignant statement of support from a bereaved mother describing the loss of her daughter, underscoring the human impact underlying the litigation.

The court emphasized that no amount of money could truly compensate class members for their injuries, emotional trauma and related expenses. Nonetheless, a settlement represents a compromise that must reflect litigation risks, delay and cost. One significant policy goal of the Benefits and Distribution Protocol was to avoid re-traumatization of class members by providing a confidential, non-adversarial process that did not require proof of causation or traditional damages. Unlike many insurance coverage cases, this decision did not turn on insurance policy wording or specific clauses; rather, it focused on the structure and fairness of the settlement scheme and the evidence related to pharmaceutical risk and causation. Where the judgment referred to “policy,” it did so in the broader sense of the design and objectives of the settlement and claims protocol, rather than contractual insurance clauses.

Approval of class counsel fees and honoraria

The court was also required to approve class counsel fees and disbursements under the statutory provisions governing agreements between lawyers and representative plaintiffs. Across the three jurisdictions, class counsel sought legal fees equal to 30% of $8,145,000, which was the settlement amount net of the $905,000 allocated to provincial health insurers. The agreement recorded that approximately 21.51% of Yasmin/YAZ distribution occurred in Ontario, 50.53% in Quebec and 27.96% in the rest of Canada. Based on this distribution, Saskatchewan’s share of the fees was $683,202.60 plus GST/PST, totalling $758,354.89—an amount significantly lower than the docketed time value. Disbursements of $252,295.53 were also claimed, for a total Saskatchewan fee and disbursement figure of $1,010,650.42, all to be paid out of the settlement proceeds rather than added on top of the settlement fund.

In assessing whether those fees were fair and reasonable and in the best interests of the class, the court considered the factual and legal complexities of a multinational pharmaceutical class action, the real possibility of losing at certification or trial, the responsibility shouldered by class counsel over many years, the monetary value of the matters in issue, the skill and competence demonstrated, the outcome obtained, and the contingency-fee nature of the retainer. The court found that class counsel had assumed significant risk in pursuing lengthy and uncertain litigation with no guarantee of success, that the contingency agreement met statutory requirements and was in line with those approved in Ontario and Quebec, and that a 30% fee was consistent with other class actions. It therefore approved the requested fees and disbursements.

Separately, the court approved a modest honorarium of $1,000 each for the Saskatchewan representative plaintiffs, recognizing their important role over 15 years in advancing access to justice for the class. The court highlighted their burdens, including providing extensive personal disclosure in discovery, maintaining communications with class members and bearing the emotional weight of both their own and others’ experiences.

Ruling and outcome

In its conclusion, the Saskatchewan court approved the Settlement Agreement, the Notices of Settlement Approval and the associated notice plan, appointed Epiq Class Action Services Canada Inc. as claims administrator, and approved class counsel’s fees, disbursements and the representative plaintiffs’ honoraria. The action was dismissed on the basis of this approved settlement, bringing the litigation to an end. The practical outcome is that the plaintiffs and class members, as the successful parties in this approval motion, gain access to a national settlement fund of $9,050,000 CAD and a streamlined, non-adversarial claims process, although the judgment does not specify the exact net monetary amount that will ultimately be distributed to individual claimants after administration costs, legal fees and health insurer allocations, so the precise total compensation in favour of class members cannot be determined from this decision alone.